share_log

Conduit Pharmaceuticals | NT 10-K: Others

Conduit Pharmaceuticals | NT 10-K: Others

Conduit Pharmaceuticals | NT 10-K:其他
美股SEC公告 ·  04/01 16:58
Moomoo AI 已提取核心信息
Conduit Pharmaceuticals Inc., previously known as Murphy Canyon Acquisition Corp., has filed a notification of late filing with the SEC for its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company, headquartered at 4995 Murphy Canyon Road, Suite 300, San Diego, CA, cited the inability to compile the necessary financial statements and related disclosures without unreasonable effort or expense as the reason for the delay. Conduit Pharmaceuticals anticipates filing the report by the extended deadline, which is the fifteenth calendar day following the original due date. The company also indicated that there would be a significant change in the results of operations compared to the previous fiscal year due to the business combination and commencement of operations as an operating company since September 2023. The notification was signed by David Tapolczay, Chief Executive Officer, on April 1, 2024.
Conduit Pharmaceuticals Inc., previously known as Murphy Canyon Acquisition Corp., has filed a notification of late filing with the SEC for its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company, headquartered at 4995 Murphy Canyon Road, Suite 300, San Diego, CA, cited the inability to compile the necessary financial statements and related disclosures without unreasonable effort or expense as the reason for the delay. Conduit Pharmaceuticals anticipates filing the report by the extended deadline, which is the fifteenth calendar day following the original due date. The company also indicated that there would be a significant change in the results of operations compared to the previous fiscal year due to the business combination and commencement of operations as an operating company since September 2023. The notification was signed by David Tapolczay, Chief Executive Officer, on April 1, 2024.
Conduit Pharmicals Inc.(前身为墨菲峡谷收购公司)已向美国证券交易委员会提交了延迟提交截至2023年12月31日财年的10-K表年度报告的通知。该公司总部位于加利福尼亚州圣地亚哥墨菲峡谷路4995号300套房,该公司指出,如果没有不合理的努力或费用,就无法编制必要的财务报表和相关披露是延迟的原因。Conduit Pharmicals预计将在延长的截止日期,即原定到期日之后的第十五个日历日之前提交报告。该公司还表示,由于业务合并以及自2023年9月以来作为运营公司开始运营,经营业绩与上一财年相比将发生重大变化。该通知由首席执行官大卫·塔波尔扎伊于2024年4月1日签署。
Conduit Pharmicals Inc.(前身为墨菲峡谷收购公司)已向美国证券交易委员会提交了延迟提交截至2023年12月31日财年的10-K表年度报告的通知。该公司总部位于加利福尼亚州圣地亚哥墨菲峡谷路4995号300套房,该公司指出,如果没有不合理的努力或费用,就无法编制必要的财务报表和相关披露是延迟的原因。Conduit Pharmicals预计将在延长的截止日期,即原定到期日之后的第十五个日历日之前提交报告。该公司还表示,由于业务合并以及自2023年9月以来作为运营公司开始运营,经营业绩与上一财年相比将发生重大变化。该通知由首席执行官大卫·塔波尔扎伊于2024年4月1日签署。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息